# Repligen Corporation – Consensus ‘buy’ rating and 26.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/repligen-corporation-consensus-buy-rating-and-26.4-upside-potential/4121129660
- Published: 2023-10-13T14:55:38+01:00
- Author: Charlotte Edwards

**Repligen Corporation** which can be found using ticker (RGEN) now have 13 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The target
price High/Low ranges between 240 and 165 and has a mean target at $197.62. Given
that the stocks previous close was at $156.35 this is indicating there is a potential
upside of 26.4%. It’s also worth noting that there is a 50 day moving average of
$163.97 while the 200 day moving average is $166.80. The company has a market cap
of 8.72B. The stock price for the company is currently 154.72 USD

 The potential market cap would be $11,018,559,803 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/
E ratio of 64.47, revenue per share of 13.12 and a 3.46% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes
bioprocessing technologies and systems that rises flexibility in the process of 
manufacturing biological drugs. The Company’s bioprocessing business consist of 
four franchises, filtration; chromatography; process analytics; and proteins. The
Filtration products are used in process development and process scale production.
The Chromatography franchise includes products used in downstream purification, 
development, and manufacturing of biological drugs. The Process Analytics products
allow end-users to make in-line absorbance measurements allowing for the determination
of protein concentration in filtration, chromatography formulation and fill-finish
applications. The Proteins franchise is represented by its Protein A affinity ligands,
which are a critical component of Protein A chromatography resins used in downstream
purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on: